The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Introduction: There are 2 misconceptions about the cerebrospinal fluid (CSF), the blood-
brain barrier (BBB), and brain drug delivery, which date back to the discovery of a barrier …

The chemogenetic technology designer receptors exclusively activated by designer drugs
(DREADDs) afford remotely reversible control of cellular signaling, neuronal activity and …

Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of
both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood …

This review considers efflux of substances from brain parenchyma quantified as values of
clearances (CL, stated in µL g− 1 min− 1). Total clearance of a substance is the sum of …

Purpose More than 15 years have passed since the first description of the unbound brain-to-
plasma partition coefficient (Kp, uu, brain) by Prof. Margareta Hammarlund-Udenaes, which …

Intracellular concentrations of drugs and metabolites are often important determinants of
efficacy, toxicity, and drug interactions. Hepatic drug distribution can be affected by many …

Mass spectrometry imaging is a field that promises to become a mainstream bioanalysis
technology by allowing the combination of single-cell imaging and subcellular quantitative …

Intracellular unbound drug concentrations determine affinity to targets in the cell interior.
However, due to difficulties in measuring them, they are often overlooked in pharmacology …

Recently, it has been proposed that drug permeation is essentially carrier-mediated only
and that passive lipoidal diffusion is negligible. This opposes the prevailing hypothesis of …